The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity ...

Weight loss with Ozempic or Wegovy can come with nausea, but avoiding certain foods and drinks can help patients manage the ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Novo Nordisk faces scrutiny after disappointing trial results for CagriSema, a next-gen obesity drug, caused a significant market valuation drop. Analysts question whether side effects limited dosage ...

After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ...

Although Novo underscored that patients in the trial achieved up to 22.7% of weight loss with CagriSema, analysts previously said they were hoping to see whether it would significantly beat Lilly’s ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...